Loading...
•
Sep 30, 2021
TherapeuticsMD Q3 2021 Earnings Report
Leadership changes were announced, including the appointment of Hugh O’Dowd as Chief Executive Officer.
Key Takeaways
TherapeuticsMD announced key leadership changes, appointing Hugh O’Dowd as CEO, succeeding Robert G. Finizio, effective on or before December 31, 2021. Finizio was appointed Vice Chair of the Board.
Hugh O’Dowd, the Company’s current President, was appointed as the Company’s Chief Executive Officer and member of the board of directors.
Robert G. Finizio, the Company’s Co-founder and current Chief Executive Officer, will be succeeded by Mr. O’Dowd, effective on or before December 31, 2021.
Mr. Finizio will continue with the Company and has been appointed Vice Chair of the Board of Directors.
Mr. O’Dowd previously served as President, Chief Executive Officer, and member of the Board of Directors of Neon Therapeutics, Inc.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...